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Abstract:
Background -Observational studies report that secretory phospholipase A2 (sPLA2) activity is a marker for CHD risk, and activity measures are thought to represent the composite activity of sPLA2-IIA, -V and -X. The aim of this study was to use genetic variants of PLA2G10, encoding sPLA2-X, to investigate the contribution of sPLA2-X to the measure of sPLA2 activity, and coronary heart disease (CHD) risk traits and outcome.
Methods and Results -Three PLA2G10 tagging SNPs (rs72546339, rs72546340, rs4003232) and a previously studied PLA2G10 cSNP rs4003228, R38C, were genotyped in a nested case:
control cohort drawn from the prospective EPIC-Norfolk Study (2175 cases and 2175 controls).
Meta-analysis of rs4003228 (R38C) and CHD was carried out using data from the Northwick Park Heart Study II and two published cohorts AtheroGene and SIPLAC, providing in total an additional 1884 cases and 3119 controls. EPIC-Norfolk subjects in the highest tertile of sPLA2 activity were older and had higher inflammatory markers compared to those in the lowest tertile for sPLA2 activity. None of the PLA2G10 tSNPs nor R38C, a functional variant, were significantly associated with sPLA2 activity, intermediate CHD risk traits or CHD risk. In metaanalysis the summary OR for R38C was OR=0.97 (95%CI 0.77-1. 22 ).
Conclusions -PLA2G10 variants are not significantly associated with plasma sPLA2 activity or with CHD risk.
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Introduction
Observational studies have identified secretory phospholipase A2 (sPLA2)-IIA mass/levels, measured by a specific ELISA, as a marker for CHD risk 1 , with elevated levels associated with an increased risk of CHD events 2-4 . In the prospective EPIC-Norfolk study, comparing the prognostic ability of sPLA2-IIA levels with sPLA2 activity, sPLA2 activity appeared to be the better risk predictor, independent of circulating sPLA2-IIA levels [5] [6] . This raised the possibility that sPLA2 activity was a composite measure of all secreted sPLA2s, including sPLA2-IIA, -V and -X and possibly -III 7 providing additional association over and above that of sPLA2-IIA levels alone. However, there is now supporting evidence that it is only sPLA2-IIA that is strongly induced under pathologic conditions associated with inflammation, tissue injury or infection, and there seems to be little evidence that other sPLA2 isoforms are present in the circulation 8, 9 .
The proatherogenic role of sPLA2-IIA (PLA2G2A) and sPLA2-V (PLA2G5) is supported by animal studies showing increased susceptibility to atherosclerosis in sPLA2-IIA (Pla2g2a) 10, 11 and sPLA2-V (Pla2g5) transgenic mice 12 . Thus by extrapolation sPLA2-X, as the most potent of the three sPLA2s in hydrolysing the most abundant phospholipid phosphotidylcholine (PC), 13 could also be considered to be pro-atherogenic and indeed it has been shown that PLA2G10 enhances foam cell formation in vitro by promoting atherogenic LDL formation 14 .
Transgenic mice over-expressing Pla2g10 have been shown to die neonatally due to severe lung pathology, suggesting a role for sPLA2-X over-expression in inflammatory airway diseases 15 .
The ELISA assay to measure circulating sPLA2-IIA mass/levels is very specific to -IIA, but no such assays exist to measure sPLA2-V or -X levels. At present, it is not possible to measure the individual contributions of these sPLA2s to plasma sPLA2 activity and the aim of bove that of sPLA2 2 2 2--II I y sPL L L LA2 A2 A2 A2-II II II IIA A A A th th th that i i i is s s s duced under pathologic conditions associated with inflammation, tissue injury or n e e p st dies sho ing increased s sceptibilit to atherosclerosis in sPLA2 IIA (Pl 2 2 ( duc c ced ed ed e u u und nd nd n er er er p pat at at thologic conditions assoc c cia ia ia i t ted with inflamm m ma a ation, tissue injury or n n nd t t t there seems to b b be e e li itt t t tle le le l evi vi vi v d de d nc n nce t tha at o oth her r s sPL PL PLA A2 A is sofo orm m ms s s a a are pr pr pr pre e esen en ent in n n t t the 8, 9 . In vitro protein expression studies led to the conclusion that R38C causes misfolding of sPLA2-X resulting in a catalytically inactive and unstable enzyme 16 . Without sPLA2 activity measures the study was unable to examine the relationship of R38C with sPLA2 activity. They also reported that R38C was not associated with CHD risk in their relatively small cohorts.
In the current paper we have taken this work forward and examined the association of the functional SNP, R38C and a number of PLA2G10 tagging (t) SNPs with sPLA2 activity, and CHD risk traits in the EPIC-Norfolk study, and with CHD events in meta-analysis of 3667 CHD cases and 4945 controls.
Methods

Study populations
The EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk study is a prospective study of 25,663 men and women aged 45-79 years, resident in Norfolk, UK, recruited from age-sex registers of general practices in Norfolk between 1993 and 1997 and followed-up for around 6 years, excluding those reporting a history of heart attack or stroke. The design and methods of the study have been described in detail 17 . The study was approved by the Norwich District Health Authority ethics committee and all participants gave signed informed consent. A nested case: control cohort was drawn from this larger study. Cases were those identified as having CHD on follow-up if they had a hospital admission and/or died with CHD as 2 activity. They als s s so o o o ly smal l l ll l l l coh h ho h t t rt ts. h S n r he cu cu curr rr rren en ent t t pa p p pe pe per r r we have taken this wor r rk k k k fo f rward and exam m mined the association SNP NP NP, R38C and nd nd a n nu u umbe be be er r of f f f P P PLA2 A A G10 0 tag ag agging ng g 18 . We included published data from AtheroGene and SIPLAC 16 in the meta-analysis of R38C on CHD.
Biochemical analysis for EPIC-Norfolk Study
Blood samples were stored at -80°C at the Department of Clinical Biochemistry, University of Cambridge. Serum levels of total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured on fresh samples with the RA 1000 (Bayer Diagnostics, Basingstoke, UK), and low-density lipoprotein cholesterol (LDL-C) levels were calculated with the Friedewald formula. Serum sPLA2 activity was measured by a selective fluorometric assay 5 by using fluorescent substrate 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3 phosphomethanol, sodium salt (Interchim, Montluçon, France), as previously described 6 . One hundred percent hydrolysis of the fluorescent substrate was measured using 0.1 U sPLA2 from bee venom (Sigma Chemical Co). The hydrolysis of substrate in the absence of plasma was used as negative control and deduced from sPLA2 activity. All samples were tested in duplicate and ne and on subseq que ue ue uent n n n les fr f f f om 2 2 2 277 77 77 775 5 5 5 me e e en n n n linked immunosorbent assay as previously described 19 . Results were related to a standard consisting of commercially available CRP (Behringwerke AG, Marburg, Germany). The lower detection limit was 0.1 mg/L.
Genotyping
We identified 10 tagging SNPs in PLA2G10 using the STRAM algorithm 20 . Seven of these tSNPs occurred at very low frequencies and were not taken forward. We genotyped EPICNorfolk for three tSNPs, rs72546339, rs72546340 and rs4003232 and also included in our study the previously reported cSNP rs4003228 (R38C) 16 . Rs72546339 and rs72546340 were genotyped using TaqMan technology (Applied Biosciences, ABI, Warrington UK). Reactions were performed on 384-well microplates and analysed using ABI TaqMan 7900HT software. Fragments were resolved using MADGE (Microtitre Array Diagonal Gel Electrophoresis) gels 21 . NPHSII was genotyped for rs4003228 (R38C) alone.
PLA2G10 mRNA expression in the ASAP Study and BiKE
Data from the Advance Study of Aortic Pathology (ASAP) was used to determine the mRNA expression levels for PLA2G10 in mammary artery, aortic media, aortic adventitia, liver and heart tissues. ASAP recruited 223 patients undergoing aortic valve surgery at the Karolinska University Hospital, Stockholm Sweden 22 . Tissue biopsies were taken from liver, mammary arteries and dilated and non-dilated ascending aorta and heart during surgery. The medial and adventitial layers of the vascular specimen were isolated by adventectomy, and incubated with RNAlater (Ambion, Austin, Texas, USA) and homogenised for mRNA extraction as previously detailed 22 . Affymetrix Gene Chip Human Exon 1.0 ST expression arrays were used. mRNA expression was evaluated using RMA pre-processing as previously described 22 . Briefly, the paper proposes to apply a quantile normalization which is an approach to make the hybridization intensity distribution of the probes in all arrays the same. The essence is that each gene is assigned a value that indicates its expression relative to all other genes. Participants were genotyped using the Illumina Human 610W-Quad Bead array 22 .
Human carotid endarterectomy samples from 127 patients undergoing surgery for asymptomatic or symptomatic carotid stenosis were part of Biobank of Karolinska Endarterectomies (BiKE) study 23 .
All samples were collected with consent from patients, organ donors or organ donors' 
Statistical analysis
The analysis was performed using Stata version 13.1 (StataCorp, Texas).
Summary statistics of the baseline characteristics were presented by tertile of sPLA2 activity and p values for trend obtained from linear regression models. Variables were logtransformed where necessary to give a normal distribution. For these variables summary statistics were back-transformed from the log scale to give the geometric mean and approximate standard deviation (SD). Geometric means and approximate SDs were also presented for sPLA2 activity by genotype. Linear regression was used to obtain beta coefficients and standard errors for the additive genetic model (both unadjusted and adjusted for age and gender) along with p values for trend. Adjustment was made for age and gender by including them as covariates in the model. Linear regression was also used to assess the effect of genotype on intermediate traits.
Association with CHD risk was determined by unconditional logistic regression analysis to obtain results consistent with those from the published studies. An additive genetic model was used. Results were adjusted for age and gender. Results from EPIC-Norfolk were then combined with those from NPHSII and the published studies SIPLAC and AtheroGene 16 using fixed effects meta-analysis to examine the association of rs4003228 (R38C) with CHD risk. 16 . For eQTL studies, association was calculated using an additive linear model in which the genotypes were numerically encoded as 0, 1, and 2.
Results
The basic characteristics of the EPIC-Norfolk case-control cohort, by tertiles of sPLA2 activity are presented in Table 1 . Compared to the lowest tertile of sPLA2 activity, those in the highest tertile were older, and had higher body mass index (BMI), blood pressure (both systolic and 
PLA2G10 gene variants and sPLA2 activity and intermediate traits
We genotyped the EPIC-Norfolk cohort for four PLA2G10 SNPs (rs4003232, rs4003228, rs72546339 and rs72546340). All genotypes were in Hardy-Weinberg equilibrium and their minor allele frequencies are given in Table 2 . In EPIC-Norfolk, none of the variants, including the functional rs4003228 (R38C) which was postulated to affect sPLA2-X activity 16 , showed an association with sPLA2 activity (additive genetic model using linear regression), but rs4003232
alone showed association with HDL-cholesterol and CRP levels (Supplementary data).
PLA2G10 R38C and CHD risk
We then concentrated on the cSNP rs4003232 (R38C). Meta-analysis was carried out on data from EPIC-Norfolk, NPHSII, SIPLAC and AtheroGene studies using fixed effects metaanalysis. The summary odds ratio was 0.97 (95%CI 0.77-1.22) (Figure 1 ).
PLA2G10 mRNA expression in ASAP and BiKE
We tested the potential allele-specific expression of PLA2G10 in the tissues available in the ASAP study, namely liver, mammary arteries, dilated and non-dilated ascending aorta and heart, from 223 patients undergoing aortic valve surgery. Overall mRNA expression of PLA2G10 was very low when compared to that of PLA2G2A and PLA2G5, as illustrated by expression in the aortic adventitia, as an example (Figure 2 ). In addition, compared to PLA2G2A 24 and PLA2G5
25
where differential mRNA expression of lead SNP reached p=8.71 x 10 -19 and 5.1 X 10 -6 , respectively, differential expression of PLA2G10 was ~1x10 -1.5 ( Figure 3) . None of our selected
SNPs of interest were present on the ASAP arrays and a limitation of these results is that only a small number of PLA2G10 specific SNPs were available on the array 22 . 
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The BiKE study, examining RNA expression in carotid endarterectomy samples from 127 individuals, enabled us to examine expression levels of PLAG10 in diseased tissue compared to controls, and PLA2G10 expression levels were similar between control and carotid endarterectomy samples (data not shown), but as with tissue from ASAP, expression levels of PLA2G10 were very low, suggesting that PLA2G10 is weakly expressed in these samples ( Figure   3 ).
Discussion
We have had a long standing interest in the sPLA2 enzymes 26,27 since they were identified as potential risk markers for CHD both from animal studies [10] [11] [12] and observational analyses. The aim of the present study was to investigate the contribution of sPLA2-X to the complex measure of sPLA2 activity, a marker of CHD risk 28 , by examining the association of PLA2G10 variants with sPLA2 activity. We also aimed to extend the work of Gora et al 16 examining, through meta-analysis, the association of PLA2G10 SNPs with CHD risk.
sPLA2 activity is not a widely available measure. For this reason we chose to study a CHD nested case-control set drawn from the EPIC-Norfolk cohort 3 , with available measures of sPLA2 activity 5 . sPLA2 is considered to be pro-inflammatory, by generating arachidonic acid which is a precursor of the inflammatory eicosanoid pathway 29 . Indeed it was evident that EPICNorfolk participants in the top tertile of sPLA2 activity had a poorer CHD risk profile than those in the lowest tertile; they were older, had a higher BMI, a worse lipid profile and increased levels of inflammatory markers CRP and sPLA2-IIA mass/ levels. Rs4003228 (R38C) was identified as a functional SNP which could strongly affect sPLA2-X activity 16 . The functional analysis of this SNP suggested that the synonymous arginine to cysteine change at codon 38 had a large impact on sPLA2-X activity in vitro with the extra, they y y y we we we were re re re i i i unpaired cysteine residue resulting in~95% decrease in sPLA2-X protein in the cell supernatant of the fibroblast-like cell line (COS cells) and ~85% decrease in the cell lysate. We were able to examine whether this SNP had an effect on sPLA2 activity in vivo. If sPLA2-X was indeed contributing to the overall measure of sPLA2 activity then we anticipated that the functional SNP R38C should show association with sPLA2 activity. Yet we found no association of R38C or the other 3 PLA2G10 tSNPs with sPLA2 activity. In addition to sPLA2-X, sPLA2 activity has been considered to result from the combined activity of sPLA2-IIA and sPLA2-V. We previously reported the association of PLA2G2A functional SNP, rs11573156, with sPLA2 activity 24, 30 , but we were unable to ratify the contribution of sPLA2-V to the overall activity measure using genetic variants of PLA2G5 25 . From this we conclude that sPLA2-V and -X play a very minor role, if any, to the measure of plasma sPLA2 activity.
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We analysed the association of the 4 PLA2G10 gene variants with a range of cardiovascular risk factors in EPIC-Norfolk. We studied anthropometric measurements (BMI, SBP and DBP), circulating cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides, and inflammatory markers (sPLA2, CRP), and we could not find an association with any intermediate CHD trait. This was in agreement with the findings Gora et al 16 .
To examine the expression of PLA2G10 we made use of data from the ASAP study.
Expression of PLA2G10 across all available tissues was considerably lower than PLA2G2A and PLA2G5 expression, and no single PLA2G10 SNP on the array had an association with differential mRNA expression. This fits with results from Kudo et al showing sPLA2-X expression was lower than sPLA2-IIA and -V in tissues such as the heart and liver 31 . Our results do not reflect the expression of PLA2G10 in tissues associated with inflammation such as thymus, spleen, leukocytes, and airways as reported elsewhere 32, 33 . Although sPLA2-X has also th sPLA2 activity ty y 24 4,3 ctivit ty y y measure us sin in in ing Referring to, but taking into account the results from Ait-Oufella et al showing anti-atherogenic effects of sPLA2-X 35 , the suggestion is that the inhibitor may at the same time reduce these antiatherogenic effects of sPLA2-X.
One limitation of our study is that the STRAM method used to select PLA2G10 tSNPs may now be outdated by more recent algorithms and data from genome wide association studies, and many of the tSNPs we identified had very low MAFs, also in agreement with those identified by Gora et al by sequence analysis 16 . R38C, although a functional SNP, has a MAF of only 0.03. Secondly our meta-analysis is powered to detect an odds ratio of CHD risk of 1.34
with 80% power at the 5% significance level, whereas the result suggests if an effect was present, it would be of smaller magnitude (likely to lie between 0.77 and 1.22). The low minor allele frequency of the R38C suggests that a larger cohort would be needed before firm conclusions can be drawn about the contribution of sPLA2-X to sPLA2 activity. The study is 90% powered to detect a medium effect size (0.5 SDs of sPLA2 activity), but to detect a small effect size (0.2 SDs) would require 5116 participants in order to have 80% power at the 5% significance level. The observed effect size is just 0.01 SDs with a confidence interval of -0.16 to 0.24. Thirdly, there has been the incorrect notion that all or most mammalian sPLA2s are induced during inflammation and can exist in the plasma. However, this is possibly only true for sPLA2-IIA and not the other sPLA2s 9, 38 , making it unlikely that sPLA2-X is a component of the plasma measure of sPLA2 activity, as supported by our results. IIE for both LDL and HDL. This order appears to roughly correlate with the ability of these sPLA2s to interact with PC-rich vesicles and with PC-rich cellular plasma membranes 8, 9 .
However the expression level of sPLA2-IIA is considerably higher than those of other sPLA2s
and it is the only sPLA2 isoform detected in the circulation of mammals (except mice) 9, 38 .
In conclusion, we conducted a genetic study to test the hypothesis that sPLA2-X contributes to plasma measures of sPLA2 activity. Our results do not support this, and may reflect the current evidence that sPLA2-X is not active in the plasma. Furthermore our results do not support the hypothesis that sPLA2-X is associated with risk of CHD. 
